Clinical Trial

MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology

Dallas, Texas, July 24, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a leader in men’s…

1 year ago

ImPact Biotech Receives a €13.5M Investment Commitment from the European Innovation Council’s Accelerator Program

TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular…

1 year ago

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),…

1 year ago

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

Presentations will include an encore of the positive interim Phase 1/2 results presented in April at the 76th Annual American…

1 year ago

Alterity Therapeutics to Present at MST Financial Webinar

MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…

1 year ago

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

Phase 2 dosing plan, agreed with FDA, paves the way to initiate patient enrollmentFOSTER CITY, Calif., July 24, 2024 (GLOBE…

1 year ago

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following…

1 year ago

Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate)…

1 year ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural…

1 year ago